The ACVR2B Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa cell line, providing targeted disruption of the human ACVR2B gene. This heterogeneous loss-of-function pool enables functional studies of ACVR2B in a widely used human cervical adenocarcinoma background without the bias of clonal selection artifacts.
HeLa cells are an aneuploid, HPV-18-positive cervical adenocarcinoma epithelial line originally isolated in 1951. Extensively characterized and employed in cancer biology, virology, and cell signaling research, these cells offer robust growth and a well-defined genomic landscape, making them a suitable host for generating gene knockouts to dissect molecular pathways in a cancer-relevant context.
ACVR2B encodes a type II serine/threonine kinase receptor for TGF-beta superfamily ligands, including activin A, myostatin, GDF11, and nodal. Ligand binding induces recruitment and phosphorylation of type I receptors ALK4 or ALK7, which subsequently phosphorylate SMAD2 and SMAD3. Phosphorylated SMAD2/3 form complexes with SMAD4 and translocate to the nucleus, regulating transcription of targets such as CDKN1A (p21) and MYC. The receptor also interacts with betaglycan (TGFBR3) and is inhibited by inhibin B, while SMAD7 provides negative feedback. This signaling cascade controls cell proliferation, differentiation, apoptosis, and muscle homeostasis, with direct implications in cancer, muscle hypertrophy, and reproductive disorders.
Ablation of ACVR2B in HeLa cells permits dissection of TGF-beta/activin/myostatin signaling contributions to cervical adenocarcinoma cell behavior. Given that HeLa cells exhibit aberrant proliferation and altered apoptotic regulation, this polyclonal knockout model reveals the specific role of ACVR2B in cancer cell growth, migration, and survival. It is particularly valuable for investigating how loss of receptor-mediated SMAD signaling influences HPV-18-positive tumor phenotypes and for evaluating ACVR2B as a potential therapeutic target in malignancies with dysregulated activin or myostatin pathways.
Typical research applications include Western blotting for ACVR2B and phospho-SMAD2/3, RT-qPCR for downstream target genes, and immunofluorescence to assess SMAD localization. Functional assays for proliferation, apoptosis, migration, and invasion, along with SMAD-responsive luciferase reporter systems and co-immunoprecipitation of receptor complexes, enable detailed mechanistic studies. These polyclonal knockout cells are suitable for drug screening campaigns targeting the activin/myostatin axis and exploring crosstalk with other signaling modules. For further technical specifications or ordering information, please contact Ascent Research.
